Effect of Chemotherapy and Reinfection on IgE-Containing and IgG-Containing Circulating Immune Complexes, Serum IgE and IgE Antibodies in Patients Chronically Infected with Schistosoma mansoni and Schistosoma haematobiumFeldmeier H. · Stevens W.J. · Bridts C.H. · Daffalla A.A. · Büttner D.W.
Abteilungen für Bakteriologie und Helminthologie, Bernhard-Nocht-Institut für Schiffs- und Tropenkrankheiten, Hamburg, FRG; Laboratory of Immunology, University of Antwerp, Belgium; National Council for Research, Khartoum, Sudan
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
The effect of chemotherapy and reinfection on circulating immune complexes (CIC), serum IgE, and parasite-specific IgE antibodies was studied in patients concomitantly infected with Schistosoma mansoni and Schistosoma haematobium. Before chemotherapy IgE- and IgG-containing CIC were present in high concentrations in all patients and IgE antibodies to S. mansoni and to S. haematobium in almost 80% of the cases. Serum IgE was excessively high (median 4,900 ku/1), but decreased to half of its initial value 2 months after chemotherapy. When reinfection with S. haematobium occurred onwards from month 4, the serum IgE reincreased and reached almost the pretreatment level at month 16. Effective chemotherapy was also followed by a rapid decrease of IgE-containing CIC and a slower, but significant, decrease of IgG-containing CIC. However, in contrast to IgE and IgE antibodies, the reinfection did not lead to a reincrease of CIC. It was interesting to note that the concentration of IgE as well as that of IgE-containing CIC was significantly correlated to the intensity of the infection. These investigations demonstrated that high levels of IgE- and IgG-containing CIC are present in chronic human schistosomiasis, but that the concentrations of CIC fall to normal values, when the parasites are eliminated by chemotherapy.
© 1983 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.